In Vitro Activity of Caspofungin against Rare Candida Species.

D. J. DIEKEMA, S. MESSER, L. BOYKEN, R. HOLLIS, S. TENDOLKAR, J. KROEGER, M. A. PFALLER;

Author address: 

Univ. of Iowa Coll. of Med., Iowa City, IA.

Abstract: 

Background: Over 95% of invasive candidiasis is caused by 5 species of Candida (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei). However, some less common Candida species have increased in incidence or caused outbreaks in healthcare facilities. While some of these rare Candida have demonstrated resistance to azoles and/or amphotericin B (e.g. C. rugosa), little is known about their susceptibility to the echinocandins. Methods: We determined the in vitro activity of caspofungin (CASP) against invasive (bloodstream or sterile site) unique patient isolates of Candida collected from 100 medical centers worldwide between January 2001 and December 2005. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI) M27-A2 method and used a 24-hour prominent inhibition endpoint for CASP MIC determination. Results: Of 10,292 invasive clinical isolates tested against CASP, 374 (4%) were among the less common species, including 117 C. guilliermondii, 128 C. lusitaniae, 51 C. kefyr, 28 C. pelliculosa, 15 C. famata, 11 C. dubliniensis, 11 C. lipolytica, 8 C. rugosa, and 5 C. zeylanoides. Overall, CASP was very active against these less common Candida species (MIC50/MIC90, 0.25/0.5 µg/ml, 97% inhibited at MIC
2006

abstract No: 

M-1582

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th